PsygaBio
Drugs Derived from Natural Compounds
StartupPsygaBio is a Caesarea-based startup in the Health Tech & Life Sciences sector, established in 2021. Drugs Derived from Natural Compounds. PsygaBio was founded by Shmuel Mandel. Key investors include NFX Capital. The company has 1-10 employees. Core technologies: Biologicals, Cells, Herbals.
The company follows a B2B business model. Product stage: R&D.
- StageSeed
- ProductR&D
- ModelB2B
- Employees1-10
- HQCaesarea
- Last RoundUndisclosed
- NFX Capital
Shmuel MandelCo-founder & CEO
What does PsygaBio do?
PsygaBio is a drug discovery company focused on developing therapeutics derived from natural compounds. Using Cannasoul's proprietary analytical platform, PsygaBio's data-driven approach, know-how, and clinical trial framework support active compound identification and development, from mushroom cultivation and extraction to clinically approved formulations. PsygaBio, in partnership with Cannasoul Analytics, aims to exploit the diversity found in the psychedelic mushroom realm to identify active compounds and formulations for therapeutic benefits. PsygaBio is a subsidiary of Cannasoul Analytics.
Who founded PsygaBio?
PsygaBio was founded in 2021 by Shmuel Mandel (Co-founder & CEO).
What sector is PsygaBio in?
PsygaBio operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Medical Cannabis, Drugs Discovery & Development, with core technologies in Biologicals, Cells, Herbals. Target customers: Healthcare & Life Sciences, Life Sciences, Biotechnology, Pharmaceuticals.
Where is PsygaBio located?
PsygaBio is based in Tarshish St 5, Caesarea, 3079822, Israel.